Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
Keith Speights has positions in Amazon, MercadoLibre, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Amazon, MercadoLibre, TransMedics Group, and Vertex Pharmaceuticals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback